Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

CAR-T Cell Therapy Shows Lasting Results in Two Pediatric Patients



While Cellectis’ immunotherapy agent is now being tested in clinical trials involving both children and adult patients, the two infant girls were the first to receive the treatment back in 2015.

Share this!

January 27, 2017 | by Sarah Hand, M.Sc.

Two pediatric patients with leukemia have been in remission for over a year after receiving experimental CAR-T cell therapy. While Cellectis’ immunotherapy agent is now being tested in clinical trials involving both children and adult patients, the two infant girls were the first to receive the treatment back in 2015.

The two girls – 11-months-old and 16-months-old at the time of treatment – are both doing well over a year after receiving the modified CAR-T cells. The doctors at Great Ormond Street Institute of Child Health, University College London, who administered the experimental treatment have now presented the case studies in an article published in the journal, Science Translational Medicine.

The cases involved the use of so-called “off-the-shelf” CAR-T cells to target cancer cells. CAR-T cell therapy normally involves gene editing a patient’s own immune cells to allow them to destroy tumor tissue.

While this approach has been shown to be relatively safe and effective, it requires an expensive and laborious procedure of collecting enough immune cells from the patient to be edited. If a patient is very young or very sick, the number of viable immune cells may be limited.

If a patient were to be infused with off-the-shelf cells which are not their own, it’s likely that the foreign cells would attack their body in a phenomenon known as graft-versus-host disease. To combat this response, pharmaceutical company Cellectis developed a gene editing tool to turn off the gene, called TCRαβ, responsible for allowing the donor cells to attack the host.

Cellectis’ gene editing tool allowed for the creation of UCART19 cells which could be universally accepted by patients with B-cell acute lymphoblastic leukemia. However, because the gene editing tool is not 100 percent accurate, both pediatric patients treated with the UCART19 cells developed some signs of graft-versus-host disease.

A gene editing technique known as TALEN was used by Cellectis to silence TCRαβ, however researchers are now looking to CRISPR for an easier and less-expensive gene editing tool. CRISPR-edited cells are now being assessed in two cancer clinical trials taking place in the US and China.

Keywords: CAR-T, Gene Editing, Leukemia


Share this with your colleagues!

Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News

New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News

Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub


Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases

Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects

Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance

Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned

Copyright © 2016-2017 Honeycomb Worldwide Inc.